Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.46 |
| ▸ | PI4KA | P42356 | 4/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587322 | 0.97 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL13587327 | 0.78 | ALDH1A1 (0.34) | ADORA3CYP1A2 | |
| SCHEMBL13587325 | 0.76 | ALDH1A1 (0.33) | ADORA3CYP1A2 | |
| SCHEMBL13587326 | 0.72 | PNP (0.38) | — | |
| SCHEMBL13587314 | 0.72 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL13587329 | 0.71 | PDE7A (0.36) | — | |
| SCHEMBL13587315 | 0.69 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL13587328 | 0.68 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL2980005 | 0.68 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL4239755 | 0.67 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | ADORA2A 47/4885ADORA1 44/4885ADORA2B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.